Kornimate/medical-research-clean huggingface dataset:
influence of nevirapine on hcv viral load

Conditions: HCV Infection.; HCV Viral Load.

Summary: nevirapine-based antiretroviral therapy is associated with lower plasma hcv viral load in hiv/hcv-coinfected individuals.


Eligibility criteria:
inclusion criteria: * hiv infection. * older than 18 years. * chronic hepatitis c. * undetectable hiv viral load during one year before starting study. * to have not received hcv therapy during one year before starting study. * to have not started efavirenz or protease inhibitors o nucleoside analogs during 6 months before starting study. * non contraindications for drugs included in this study. * to change an antiretroviral regimen including efavirenz or protease inhibitors by nevirapine due to side effects, interactions or pregnancy (nvp group) * to continue with a antiretroviral regimen including efavirenz or protease inhibitors (non-nvp group) both groups will be matched according to these variables: * liver stiffness. * hcv genotype. * hospital. * time from starting antiretroviral therapy. * previous third drug (efv or pi) to introduction of nvp. exclusion criteria: * hcv therapy during follow-up

Keywords: hcv hiv nevirapine hcv viral load efavirenz protease inhibitors
serological screening of gastric cancer in wuxi region

Conditions: Stomach Neoplasms

Summary: the purpose of this study is to determine whether detection of pepsinogen ⅰand ⅱ combined with helicobacter pylori antibody, so-called abc method , is fit on gastric cancer screening in community of wuxi city.

gastric cancer is the third largest cause of cancer related deaths in china with about 350 ,000 gastric cancer-related deaths by gastric cancer in 2012. the studies from japan and korea have found gastric cancer screening, especially of the mass population, reduces mortality from gastric cancer, but the data is seldom in china. the ways include radiographic and endoscopic screening, although those methods were shown to reduce gastric cancer mortality, and was recommended as gold standard for population-based screening by japan and korea, but many problems have been pointed out: a serious drawback is low uptake of the target population; fear for radiation exposure(0.6 msv), swallowing unpleasantness due to the use of barium meal, accidental fall during the examination and constipation, causing rare but more serious complications such as intestinal obstruction or diverticulitis after examination may account for the reasons for this low uptake, endoscopic screening is labor-intensive, more costly per examination as complete disinfection of the scope is mandatory, and requires a large number of well-trained experienced endoscopists. serological method, so-called abc method , has been useful as gastric cancer preliminary screening in some areas, such as china, japan and korea. the major reasons are attributed to its simplicity, safety (radiation-free, discomfort free), and cost-efficiency. the abc method is a blood test to stratify the risk of gastric cancer using the combination of h. pylori antibody and pepsinogen i and ii, that was documented by large-scale studies in japan. but the data was short in china, especially in the community.

Eligibility criteria:
inclusion criteria: age 40-70 years old, men and women are not limited, and there are one of the following: 1. hp infected. 2. previously suffering from chronic atrophic gastritis, gastric ulcer, gastric polyps, hypertrophic gastritis, pernicious anemia and other precancerous diseases of the stomach. 3. first degree relatives of patients with gastric cancer. 4. other risk factors for gastric cancer. (high salt, salted diet, smoking, heavy drinking, etc.) exclusion criteria: 1. severe heart, liver, kidney, dysfunction or mental disorders 2. history of gastric surgery (including surgery, minimally invasive emr, esd) 3. use of ppi, acid preparation, stomach protecting agent in the first two weeks 4. the researchers considered inappropriate participants. 5. informed consent cannot be attained

Keywords: pepsinogen ⅰ pepsinogen ⅱ gastric cancer screening helicobacter pylori gastrin
using capnography to reduce hypoxia during pediatric sedation

Conditions: Hypoventilation; Hypoxia

Summary: the investigators hypothesize that the addition of capnography during moderate sedation will improve recognition of hypoventilation and apnea. this will lead to an increased frequency of staff interventions such as verbal or physical stimulation for these events in order to improve ventilation which will in turn lead to a reduction in the frequency of oxygen desaturations. if capnography proves to be effective in creating earlier detection and intervention for hypoventilation and apnea during moderate sedation provided by non-anesthesiologists, this device can be used in a variety of clinical settings to enhance patient safety.


Eligibility criteria:
inclusion criteria: * children 1-20 years old who require iv sedation in the pediatric emergency department at yale-new haven children's hospital exclusion criteria: * unable to tolerate nasal-oral cannula * conditions that effect end-tidal carbon dioxide measurement (active asthma, diabetic ketoacidosis, severe dehydration or trauma) * intubation

Keywords: hypoventilation during sedation hypoxia associated with hypoventilation
study of esomeprazole 20 mg or 40 mg vs placebo effectiveness on the occurrence of peptic ulcers in subjects on low dose acetylsalicylic acid (lda)

Conditions: Gastric Ulcer; Duodenal Ulcer

Summary: the purpose of this study is to compare the effect of esomeprazole 20 or 40 mg once daily versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low-dose acetylsalicylic acid.


Eligibility criteria:
inclusion criteria: * daily intake of low-dose aspirin (asa) - the subject must fulfill at least one of the following (a-e): * aged ≥65 years. * aged ≥18 years and with a documented history of uncomplicated peptic ulcer(s). * aged ≥60 years and naïve to low-dose asa (ie, treatment started within 1 month prior to randomization). * aged ≥60 years and with stable coronary artery disease. * aged ≥60 years and with complaints of upper gastrointestinal (gi) symptoms that, as judged by the investigator, requires an esophagogastroduodenoscopy (egd) and with the finding of ≥5 gastric and/or duodenal erosions at the baseline endoscopy. exclusion criteria: * peptic ulcer(s) at baseline esophagogastroduodenoscopy (egd). * reflux esophagitis los angeles (la) classification grade c or d at baseline * history of peptic ulcer complications such as clinically significant bleeding and/or perforation.

Keywords: peptic ulcer low-dose asa
oral iron frequency for childhood restless leg syndrome/periodic limb movement disorder

Conditions: Sleep Disorder; Restless Legs Syndrome; Periodic Limb Movement Sleep Disorder; Iron-deficiency

Summary: the purpose of this research study is to see if the level of serum ferritin differs based on how often oral iron (in the form of ferrous sulfate) is given to children with restless leg syndrome/periodic limb movement disorder.


Eligibility criteria:
inclusion criteria: * ferritin equal to or lower than 24 mcg/l drawn within the last 30 days. * age 2 to 10 years. * diagnosis of restless leg syndrome, periodic limb movement disorder, or sleep disturbance. exclusion criteria: * currently taking oral formulation of iron other than a multivitamin. * untreated obstructive sleep apnea. * gastrointestinal disorder, including gastroesophageal reflux disease and celiac disease. * prior gastrointestinal surgery; e.g., gastrectomy, duodenal bypass, and presence of g-tube. * use of h2 blocker, antacid, or proton pump inhibitor. * inflammatory disorders, including juvenile idiopathic arthritis or inflammatory bowel disease. * elevated crp at time of initial ferritin or report of illness in past 4 weeks.
comparison of neuro-navigational systems for resection-control of brain tumors

Conditions: Glioma

Summary: purpose: * improvement of extent of resection by the use of intraoperatively acquired image data sets to navigate. * better define the role of different intra-operative imaging modalities, used to update the navigational data set, in aiding the surgeon during resection of intra-axial brain lesions. * to examine the cost-effectiveness of different intraoperative navigational systems as a function of operative time and operative time (surgery including imaging) there is increasing neuro-oncological evidence that extent of resection might have an impact in particular in low-grade lesions.


Eligibility criteria:
inclusion criteria: * patients must have neuro-radiological evidence of a brain lesion. eligible are all histological types of brain lesions. * \> 18 years of age. * male and female. * patient must be a surgical candidate, according to general anesthetic and neurosurgical criteria. * patient should be able to undergo mri. * informed consent as per protocol. exclusion criteria: * patient unwilling to undergo surgery for resection of brain tumor. * patient medically not eligible to undergo craniotomy. (medical contraindication). * patient has a medical contraindication or is unwilling to undergo mri scanning (pacemaker, other metal device ot parts in head or body,). * kidney function compromise (creatinine values \> 1.4 mg/dl).

Keywords: glioma intraoperative mr intraoperative ultrasound resection intraoperative navigation extent of resection
the role of peritoneal dialysis in patients with refractory heart failure and chronic kidney disease

Conditions: Refractory Heart Failure; Chronic Kidney Disease

Summary: in patients with advanced heart failure (hf), systemic congestion is the main indication for hospitalization. recent evidence has highlighted the role of fluid retention in the pathogenesis of renal dysfunction and subsequent diuretic resistance. previous kidney disease, diuretic resistance, and progression of renal dysfunction often coexist in patients with hf and persistent volume overload. this clinical presentation represents the most extreme feature of the cardio-renal syndrome. however, available therapeutic options for this ominous condition are scarce and limited. indeed, there are no data from randomized control trials using pharmacological interventions that support the beneficial effect on survival. interestingly, intermittent ultrafiltration has recently emerged as an alternative therapeutic option for reducing volume overload in patients with refractory hf. current literature suggests that it has potential advantages over standard medical treatment particularly in acute stages of hf. among ultrafiltration methods, peritoneal dialysis (pd) has been preferred as an additional resource for the treatment of advanced congestive heart failure (chf) compared with hemodialysis because it can provide a more physiological and continuous ultrafiltration. in fact, several studies showed that use of pd improved clinical functional class and hemodynamic parameters and reduced hospitalization rates in patients with chf. nevertheless, most studies were limited by retrospective analyses of small sample size, prospective observational design with no control group, or inclusion of patients with end-stage renal failure. therefore, well-designed prospective randomized controlled studies are mandatory to confirm the effects of pd in these patients.


Eligibility criteria:
inclusion criteria: 1. at least two non-planned admissions for acute heart failure (ahf), the last episode being in the past 6 months 2. new york heart association (nyha) functional class iii/iv and left ventricular ejection fraction (lvef) less than 40% 3. persistent congestion despite optimal loop diuretic therapy 4. presence of renal dysfunction \[estimated glomerular filtration rate (egfr) \< 30 ml/min/1.73 m2\] documented at least once in the last 6 months exclusion criteria: 1. \< 20 years of age 2. pregnancy 3. unsuitable for pd (patients with major abdominal wall defects) 4. allergic to starch or other contraindication to icodextrin (5) end-stage renal disease (egfr \< 10 ml/min/1.73 m2) requring dialysis treatment

Keywords: peritoneal dialysis, chronic kidney disease, refractory heart failure
the e-series registry for supralimus® coronary stent for the treatment of unselected patients with coronary lesions

Conditions: Coronary Artery Disease

Summary: e-series registry evaluate the procedural and clinical outcomes of the supralimus® ses in the treatment of unselected, high risk patients having coronary artery blockage in the real world clinical practice.

e-series registry is prospective, multinational (asia, south america and europe), non-randomized, post-marketing web-based registry. for this study up to 100 clinical sites in asia, south america and europe. patients "all comers" assigned for percutaneous coronary interventions who present with at least one angiographically documented coronary artery lesion suitable for percutaneous treatment with the supralimus® ses. all subjects who provided signed informed consent prior to procedure, and have at least one lesion in a major epicardial vessel or major branch (\>2.25mm), and are suitable for percutaneous treatment including stenting procedure with the supralimus® ses. there are no limit regarding the number of lesions and/or study stents to be used, and stenting technique will be left at the operator's discretion; however, it is recommended according to the best interventional practice according to the current guidelines. all patients will undergo follow-up clinical evaluation at 1, 6, 12 and 24 months. angiographic follow-up will be performed at 6 months in a subset of high risk lesions including bifurcations (first 100 lesions) and left main stem (first 100 lesions).

Eligibility criteria:
inclusion criteria: 1. clinical inclusion criteria: patients \>18 years, clinical indication for elective or emergency percutaneous coronary intervention with stent implantation of at least one angiographically documented coronary artery lesion; agreement to undergo all study protocol follow-ups. 2. angiographic inclusion criteria: diseased coronary vessels with at least one lesion with ≥50% diameter stenosis by visual estimation in a major epicardial vessel or a major branch (\>2.25mm) with anatomy suitable for percutaneous treatment with the supralimus ses. exclusion criteria: 1. clinical exclusion criteria: known illness with life expectancy \<12 months; impossibility to comply with all protocol follow-ups. 2. angiographic exclusion criteria: anatomy unsuitable for percutaneous treatment with implantation of the supralimus ses.

Keywords: coronary artery disease restenosis stent thrombosis coronary stents angioplasty drug eluting stents(des)
palliative radiation oncology chief's clinic

Conditions: Malignant Disease; Metastasis

Summary: the proposed study represents a quality improvement study of a recently-developed dedicated radiation oncology subspecialty clinic with the goal of improving timeliness of palliative radiation therapy and improving resident training in palliative care topics. the aim of this study is to evaluate the impact of this clinic on time to palliative radiation therapy following referral.

primary objective: • determine whether interval between palliative radiation therapy referral and palliative radiation therapy initiation is shorter for participants treated in a dedicated palliative radiation oncology clinic compared to the same interval for participants treated in a general radiation oncology clinic (historical control). the investigators' hypothesis is that this interval will be significantly shorter among the palliative radiation oncology chief's clinic participants compared to historical control. secondary objectives: * determine whether each of the three component intervals within the overall interval from referral to treatment initiation (i.e., referral to consultation; consultation to simulation; simulation to treatment) is shorter for participants treated in a dedicated palliative radiation oncology clinic compared to the length of the same intervals for participants treated in a general radiation oncology clinic (historical control). the investigators' hypothesis is that each of these component intervals will be significantly shorter among the palliative radiation oncology chief's clinic participants compared to historical control. * describe levels of and changes over time in patient-reported quality of life after palliative radiation therapy in the full sample, and in subgroups stratified by various radiation regimens. the investigators' hypothesis is that participants who receive a shorter course of palliative radiation (one day or five days) will have greater improvements in overall quality of life than participants who receive a ten-day course of palliative radiation. * determine median overall survival after palliative radiation therapy.

Eligibility criteria:
inclusion criteria: * age 18 years or older * clinically or pathologically-defined malignant disease amenable to palliative radiotherapy. exclusion criteria: * pregnancy. a verbal pregnancy denial will suffice. * no intention to treat with palliative radiation therapy following initial referral and consult.

Keywords: difficult to treat cancers
memory preservation of hippocampal avoidance whole brain radiotherapy

Conditions: Brain Metastases; Neurocognitive Function

Summary: the study aimed to investigate the memory preservation and neurocognitive function protection of hippocampal avoidance whole brain radiotherapy (ha-wbrt) among people who speak mandarin chinese or taiwanese.

brain metastasis is very common, about 30% incidence rate for all patients with a diagnosis of cancer. the rising incidence of brain metastasis is most likely due to recent advances in systemic therapy, and use of magnetic resonance imaging (mri). the most common primary site is the lung followed by breast. one of the standard treatments is whole brain radiotherapy; it can prolong the decline of neurocognitive function and improve quality of life. however, it can also cause decline in neurocognitive function as a late sequela. memory impairment is the main cognitive function that affected by radiotherapy, and the neuronal stem cells located at hippocampal subgranular zone are highly sensitive to radiotherapy. there have been large randomized trials confirming that by ha-wbrt, the neurocognitive function decline can be reclaimed. in taiwan, ha-wbrt is a popular and emerging treatment. however, not much study focused on its effects on neurocognitive function. the study is aimed to objectively investigate the memory preservation and neurocognitive function protection of ha-wbrt in people speaking mandarin chinese or taiwanese by utilizing neurocognitive function test and qol questionnaire.

Eligibility criteria:
inclusion criteria: * patients with brain metastases, the brain metastases are located 5mm outside the hippocampus * pathologically proven diagnosis of nonhematopoietic malignancy other than germ cell malignancy * no psychologic disorders * radiation therapy oncology group recursive partitioning analysis class i or ii * first or second language: mandarin chinese or taiwanese * signed the inform consensus exclusion criteria: * less than 20 years old * leptomeningeal metastases or hydrocephalus * previous radiotherapy to head and neck region * creatinine \>1.5mg/dl * more than 2 extracranial metastases * patients who cannot tolerate memory or neurocognitive function test or cannot complete qol questionnaire

Keywords: hippocampal avoidance whole brain radiotherapy (ha-wbrt) brain metastases memory preservation neurocognitive function
impact of a multimodal prehabilitation program before robotic-assisted radical prostatectomy.

Conditions: Prostate Cancer

Summary: the aim of the study is to verify whether a multimodal prehabilitation programme prior to robotic radical prostatectomy contributes to a faster recovery of quality of life after surgery, to better functional results (including erectile function and continence) and to less perioperative anxiety.

single center randomized clinical trial including prostate cancer patients undergoing robotic-assisted radical prostatectomy at the hospital clínic de barcelona. patients will be randomized into two groups, one receiving multimodal prehabilitation and the other a control group. multimodal prehabilitation consists of improving the functional and mental capacity of an individual to cope with a significant stressor, in this case surgery. the design of our prehabilitation program, lasting 4 weeks prior to surgery, consists of three parts; physical state, nutritional state and mental health. in the case of physical condition, a series of supervised and "home-based" exercises (aerobic and functional) will be carried out in addition to specific pelvic floor exercises. the nutritional status will be evaluated by a nutritionist. diet guidelines will be given and if there are deficiencies they will be supplemented. regarding mental health, a visit will be made with a psychologist and group and online therapies will be offered. the outcomes will be evaluated before starting the prehabilitation program, at the end of it (just before surgery) and at 4, 8 and 16 weeks after surgery. the outcomes include variables on physical, nutritional and mental state, health-related quality of life (hrqol), and continence and erectile function.

Eligibility criteria:
inclusion criteria: * patients with localized prostate cancer * candidates to robotic radical prostatectomy exclusion criteria: * non-localized prostate cancer * previous history of pelvic radiotherapy or pelvic surgery * failure to consent, * unwillingness to participate * anticipated failure to adhere to the program sessions.
alternating pressure air mattress and pressure injury prevalence

Conditions: Pressure Injury; Alternating Pressure Air Mattress; Implementation

Summary: explore the correlation of accurate implementation of apam and pressure injury prevalence


Eligibility criteria:
inclusion criteria: patients with pressure injury exclusion criteria: -
a study to learn about the safety and immune response of 20vpnc in adults in india.

Conditions: Pneumococcal Disease

Summary: the purpose of this study is to learn about the safety and immune response of 20vpnc in adults in india. this study is seeking participants who: * are generally healthy adults of 18 years or older. * have not received pneumococcal vaccine. the study will have 2 groups based on age. one group will have particpants between 18 to 49 years of age. the other group will have participants of 50 years or older. participants will take part in the study for about one month which includes two visits to the study clinic. participants will receive a single dose of study vaccine (20vpnc) into the arm at visit 1 and will come to study site for a follow-up visit after about a month. the study team will ask questions about the participant's health and blood samples will be taken in a subset of participants during the visits.


Eligibility criteria:
inclusion criteria: - generally healthy participants ≥18 years of age at the time of consent. exclusion criteria: * history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of 20vpnc, or to any other diphtheria toxoid-containing vaccine. * known or suspected immune deficiency or suppression. * other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * previous vaccination with any pneumococcal vaccine, or planned receipt of any pneumococcal vaccine through study participation.